A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
This clinical trial tests how well a digital treatment platform using a mobile application works for the delivery of home-based sequential therapy in patients with glioma. Access to specialized neuro-oncology care in the United States for patients with glioma is critically deficient. Care at centers with neuro-oncology specialists is associated with improved survival outcomes, yet many patients have limited access due to distance, disease-related disability, or lack of financial resources. The application provides patients continuous access to their care team in the home setting. A digital treatment platform may increase clinical trial participation and accelerate development of novel therapeutics while addressing a great health disparity in patients with glioma.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Diagnosis of glioma and intention to treat with either new or ongoing systemic therapy for at least 6 months.
NOTE: Patient may be enrolled following completion of surgery and/or radiation therapy for newly diagnosed or recurrent tumor.
NOTE: Any number of prior recurrences is permitted
Disqualifiers
Pregnant or nursing, imprisoned, or lacking capacity for understanding
Uncontrolled and/or intercurrent illness or other condition which limits safety of or compliance with study proceedings
Trial design
Treatments tested in this trial
- Chemotherapy
- Computed Tomography
- Internet-Based Intervention
- Magnetic Resonance Imaging
- Neurologic Examination
- Questionnaire Administration
- Surveillance
Treatment groups
120 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov